Market share of cardiovascular internal drugs in China 2015-H1 2022
In the first half of 2022, Yiling Pharmaceutical's cardiovascular internal drugs had a market share of almost 17 percent in the public healthcare market in China. In recent years, the market share showed constant fluctuations.